AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31230119 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular hyaluronic acid injection (3 injections weekly starting immediately after ORIF)
Number of subjects: 40
Study 31230119 — intervention group
Group type: COMPARATOR
Intervention: Control group (no injection after ORIF)
Number of subjects: 40
Study 28045979 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive diabetes self-management education (DSME) programme for six months
Number of subjects: 118
Study 28045979 — intervention group
Group type: COMPARATOR
Intervention: Conventional education for six months
Number of subjects: 118
Study 26345817 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence to GOLD guidelines (intervention group)
Number of subjects: 102
Study 26345817 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized management (intervention group)
Number of subjects: 102
Study 26345817 — intervention group
Group type: COMPARATOR
Intervention: Control group (no adherence to GOLD guidelines)
Number of subjects: 102
Study 23297711 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (5-10 mg/day)
Number of subjects: 20
Study 23297711 — intervention group
Group type: COMPARATOR
Intervention: Valsartan (80-320 mg/day)
Number of subjects: 20
Study 22067476 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide (5 μg bolus in 30 minutes followed by continuous infusion of 20 μg/24 h for 72 h)
Number of subjects: 108
Study 22067476 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 108
Study 17614243 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandatory treatment for repeat DUI offenders
Number of subjects: 233
Study 16925757 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel (70 mg/m² intravenously on day 2 every 21 days) and estramustine (3 x 280 mg/day oral for 5 consecutive days) with dexamethasone (16 mg total daily dose for 5 days)
Number of subjects: 72
Study 16925757 — intervention group
Group type: COMPARATOR
Intervention: Estramustine (3 x 140 mg/day oral for 3 consecutive days) with dexamethasone (16 mg total daily dose for 3 days)
Number of subjects: 72
Study 12924097 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated split trivalent influenza vaccine (IIV), administered parenterally
Number of subjects: 159
Study 12924097 — intervention group
Group type: EXPERIMENTAL
Intervention: Live cold‐adapted reassortant trivalent influenza vaccine (LIV), administered intranasally
Number of subjects: 159
Study 12924097 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of both vaccines
Number of subjects: 159
Study 12924097 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 159
Study 10753249 — intervention group
Group type: EXPERIMENTAL
Intervention: Plant stanol ester margarine
Number of subjects: 81
Study 10753249 — intervention group
Group type: COMPARATOR
Intervention: Control margarine
Number of subjects: 81
Study 8777253 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy
Number of subjects: 0
Study 8777253 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy
Number of subjects: 0
Study 8777253 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of taxoids
Number of subjects: 0
Study 8777253 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy before surgery
Number of subjects: 0
Study 1576325 — intervention group
Group type: EXPERIMENTAL
Intervention: Terfenadine after a high fat breakfast
Number of subjects: 0
Study 1576325 — intervention group
Group type: COMPARATOR
Intervention: Terfenadine while fasting
Number of subjects: 0
Study 2408319 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextran 70
Number of subjects: 19
Study 2408319 — intervention group
Group type: COMPARATOR
Intervention: Donor plasma
Number of subjects: 19
Study 30440099 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) applied during surgical procedure
Number of subjects: 100
Study 30440099 — intervention group
Group type: COMPARATOR
Intervention: Control group (received no PRP injection)
Number of subjects: 100
Study 30360965 — intervention group
Group type: EXPERIMENTAL
Intervention: Erenumab 140 mg (via two 70 mg injections) every 4 weeks for 12 weeks
Number of subjects: 246
Study 30360965 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 246
Study 27449267 — intervention group
Group type: EXPERIMENTAL
Intervention: Applied Behavior Analysis (ABA)
Number of subjects: 6
Study 27449267 — intervention group
Group type: COMPARATOR
Intervention: Modified Sequential Oral Sensory Approach (M-SOS)
Number of subjects: 6
Study 27449267 — intervention group
Group type: EXPERIMENTAL
Intervention: Applied Behavior Analysis (ABA) after M-SOS
Number of subjects: 6
Study 24586031 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential therapy - 20 mg omeprazole and 1 g amoxicillin for 5 days, followed by 20 mg omeprazole, 500 mg clarithromycin and 500 mg tinidazole for the successive 5 days
Number of subjects: 0
Study 24586031 — intervention group
Group type: COMPARATOR
Intervention: 5 day concomitant therapy - 20 mg omeprazole, 1 g amoxicillin, 500 mg clarithromycin and 500 mg tinidazole for 5 days
Number of subjects: 0
Study 24586031 — intervention group
Group type: EXPERIMENTAL
Intervention: 14 day concomitant therapy - 20 mg omeprazole, 1 g amoxicillin, 500 mg clarithromycin and 500 mg tinidazole for 14 days
Number of subjects: 0
Study 24586031 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid therapy - 20 mg omeprazole and 1 g amoxicillin for 7 days, followed by 20 mg omeprazole, 1 g amoxicillin, 500 mg clarithromycin and 500 mg tinidazole for the successive 7 days
Number of subjects: 0
Study 22157137 — intervention group
Group type: EXPERIMENTAL
Intervention: Adolescent Asthma Action program
Number of subjects: 261
Study 20019107 — intervention group
Group type: EXPERIMENTAL
Intervention: CE-MRA at 1.5T
Number of subjects: 58
Study 20019107 — intervention group
Group type: EXPERIMENTAL
Intervention: CE-MRA at 3T
Number of subjects: 58
Study 20019107 — intervention group
Group type: EXPERIMENTAL
Intervention: TOF-MRA at 1.5T
Number of subjects: 58
Study 20019107 — intervention group
Group type: EXPERIMENTAL
Intervention: CE-MRA at 1.5T and 3T
Number of subjects: 58
Study 17942471 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal testosterone (5 or 10 g/day) and rhGH (0, 3, or 5 microg/kg/day) for 16 weeks
Number of subjects: 112
Study 15020610 — intervention group
Group type: EXPERIMENTAL
Intervention: Three to four courses of high-dose cytarabine (HDAC)
Number of subjects: 48
Study 15020610 — intervention group
Group type: COMPARATOR
Intervention: One course of high-dose cytarabine (HDAC) followed by alternative intensive consolidation therapy
Number of subjects: 48
Study 11937116 — intervention group
Group type: EXPERIMENTAL
Intervention: Dienogest, 1 mg tablet daily for 16 weeks
Number of subjects: 142
Study 11937116 — intervention group
Group type: COMPARATOR
Intervention: Decapeptyl, 3.75 mg IM injection every 4 weeks for 16 weeks
Number of subjects: 142
Study 9523365 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxic ventilatory response (HVR) during severe hypoxia (PETO2 from 60 to 35 mm Hg) in PD patients
Number of subjects: 24
Study 9523365 — intervention group
Group type: EXPERIMENTAL
Intervention: Alveolar ventilation while breathing air in PD patients
Number of subjects: 24
Study 9523365 — intervention group
Group type: EXPERIMENTAL
Intervention: PETO2 while breathing air in PD patients
Number of subjects: 24
Study 9523365 — intervention group
Group type: EXPERIMENTAL
Intervention: PETCO2 while breathing air in PD patients
Number of subjects: 24
Study 9523365 — intervention group
Group type: EXPERIMENTAL
Intervention: HVR during minor hypoxia (PETO2 from 100 to 60 mm Hg)
Number of subjects: 24
Study 8994987 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional CO2 pneumoperitoneum
Number of subjects: 25
Study 8994987 — intervention group
Group type: COMPARATOR
Intervention: Mechanical abdominal wall lift (AWL) method with minimal CO2 insufflation
Number of subjects: 25
Study 2017647 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone (single intramuscular dose)
Number of subjects: 0
Study 2017647 — intervention group
Group type: COMPARATOR
Intervention: Rifampin (standard regimen)
Number of subjects: 0
Study 7038842 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination chemotherapy with 5-FU and BCNU
Number of subjects: 40
Study 7038842 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 31847246 — intervention group
Group type: COMPARATOR
Intervention: LC-CON
Number of subjects: 58
Study 31847246 — intervention group
Group type: EXPERIMENTAL
Intervention: LC-HIIT
Number of subjects: 58
Study 31847246 — intervention group
Group type: EXPERIMENTAL
Intervention: LC-MICT
Number of subjects: 58
Study 28372791 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive plate osteosynthesis (MIPO)
Number of subjects: 107
Study 28372791 — intervention group
Group type: COMPARATOR
Intervention: Open plating
Number of subjects: 107
Study 23716985 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucomannan (GNN) at a dosage of 2.52 g/d (1 sachet of 1.26 g 2 times a day) for 4 weeks
Number of subjects: 84
Study 23716985 — intervention group
Group type: COMPARATOR
Intervention: Placebo (maltodextrin) at the same dosage for 4 weeks
Number of subjects: 84
Study 21846985 — intervention group
Group type: EXPERIMENTAL
Intervention: Once daily gentamicin dosing
Number of subjects: 71
Study 21846985 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice daily gentamicin dosing
Number of subjects: 71
Study 21846985 — intervention group
Group type: COMPARATOR
Intervention: Both dosing regimens
Number of subjects: 71
Study 19682220 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser-welded titanium bars
Number of subjects: 8
Study 19682220 — intervention group
Group type: COMPARATOR
Intervention: Cast alloy bars (Au-Ag-Pd, Pd-Ag-Au, Au-Ag-Cu-Pd, Ag-Pd-Cu-Au)
Number of subjects: 8
Study 19682220 — intervention group
Group type: EXPERIMENTAL
Intervention: Tightening sequence (distal ends first)
Number of subjects: 8
Study 17926624 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at Hegu (LI 4), Neiguan (PC 6), and Zusanli (ST 36) combined with oral administration of Lidocaine
Number of subjects: 97
Study 17926624 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine administration only
Number of subjects: 97
Study 15523006 — intervention group
Group type: EXPERIMENTAL
Intervention: Serial casting combined with botulinum toxin A (Botox) injection
Number of subjects: 23
Study 15523006 — intervention group
Group type: COMPARATOR
Intervention: Serial casting only
Number of subjects: 23
Study 11720760 — intervention group
Group type: EXPERIMENTAL
Intervention: Platin-based combination chemotherapy
Number of subjects: 0
Study 11720760 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel 75 mg/m2 every 3 weeks
Number of subjects: 0
Study 11720760 — intervention group
Group type: COMPARATOR
Intervention: Single agent therapy with newer cytotoxic agents
Number of subjects: 0
Study 11720760 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Number of subjects: 0
Study 9246961 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrauterine insemination (IUI) combined with superovulation
Number of subjects: 70
Study 9246961 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct intraperitoneal insemination (DIPI) combined with superovulation
Number of subjects: 70
Study 9246961 — intervention group
Group type: EXPERIMENTAL
Intervention: Timed intercourse (TI) combined with superovulation
Number of subjects: 70
Study 9246961 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments combined (IUI, DIPI, TI) with superovulation
Number of subjects: 70
Study 7686101 — intervention group
Group type: EXPERIMENTAL
Intervention: Training in rhyming tasks
Number of subjects: 47
Study 7686101 — intervention group
Group type: EXPERIMENTAL
Intervention: Training in blending tasks
Number of subjects: 47
Study 7686101 — intervention group
Group type: EXPERIMENTAL
Intervention: Training in segmenting tasks
Number of subjects: 47
Study 7686101 — intervention group
Group type: COMPARATOR
Intervention: Control group (no phonological task training)
Number of subjects: 47
Study 3720306 — intervention group
Group type: EXPERIMENTAL
Intervention: Condoms exposed to UV light for 10 hours
Number of subjects: 130
Study 3720306 — intervention group
Group type: EXPERIMENTAL
Intervention: Condoms exposed to UV light for 5 hours
Number of subjects: 130
Study 3720306 — intervention group
Group type: EXPERIMENTAL
Intervention: Unexposed condoms
Number of subjects: 130
Study 3720306 — intervention group
Group type: EXPERIMENTAL
Intervention: Condoms aged for over 40 months under field conditions
Number of subjects: 130
Study 29952106 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy with fractional radiofrequency microneedling and 5% topical minoxidil
Number of subjects: 19
Study 29952106 — intervention group
Group type: COMPARATOR
Intervention: Monotherapy with 5% topical minoxidil
Number of subjects: 19
Study 26351332 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel plus trastuzumab plus pertuzumab (THP)
Number of subjects: 0
Study 26351332 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel plus trastuzumab (TH)
Number of subjects: 0
Study 24905061 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone (RSG)
Number of subjects: 73
Study 24905061 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (MET)
Number of subjects: 73
Study 24905061 — intervention group
Group type: COMPARATOR
Intervention: Rosiglitazone (RSG) to Metformin (MET)
Number of subjects: 73
Study 23479456 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive mandibular extension for 10 minutes with partial active masticatory movements
Number of subjects: 18
Study 23479456 — intervention group
Group type: COMPARATOR
Intervention: Control conditions (same overall duration without stimulation)
Number of subjects: 18
Study 19017296 — intervention group
Group type: COMPARATOR
Intervention: Active girls
Number of subjects: 346
Study 19017296 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedentary girls
Number of subjects: 346
Study 19017296 — intervention group
Group type: EXPERIMENTAL
Intervention: Active boys
Number of subjects: 346
Study 19017296 — intervention group
Group type: COMPARATOR
Intervention: Sedentary boys
Number of subjects: 346
Study 18564781 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% polyhexanide gel (Prontosan Gel)
Number of subjects: 0
Study 15717189 — intervention group
Group type: EXPERIMENTAL
Intervention: Needle technique for obtaining autologous cancellous bone
Number of subjects: 50
Study 15717189 — intervention group
Group type: COMPARATOR
Intervention: Open technique for obtaining autologous cancellous bone
Number of subjects: 50
Study 12456422 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 4 mg plus droperidol 1.25 mg after induction and droperidol 1.25 mg 12 h later (Group 1)
Number of subjects: 90
Study 12456422 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 4 mg plus dexamethasone 8 mg after induction and placebo 12 h later (Group 3)
Number of subjects: 90
Study 12456422 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone 8 mg plus droperidol 1.25 mg after induction and droperidol 1.25 mg 12 h later (Group 2)
Number of subjects: 90
Study 10605163 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin (CBCDA) 300 mg/m2 day 1, Vindesine (VDS) 3 mg/m2 days 1 and 5, leucovorin (L) 100 mg/m2, 5‐fluorouracil (5‐FU) 370 mg/m2 for 5 days, and 13‐cis retinoic acid (R) 1 mg/kg, administered between chemotherapy courses.
Number of subjects: 28
Study 7854518 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients who had seizures
Number of subjects: 58
Study 7854518 — intervention group
Group type: COMPARATOR
Intervention: Patients who did not have seizures
Number of subjects: 58
Study 7854518 — intervention group
Group type: EXPERIMENTAL
Intervention: Timing of seizures
Number of subjects: 58
Study 7854518 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of seizures
Number of subjects: 58
Study 1881957 — intervention group
Group type: COMPARATOR
Intervention: Sham ultrasound using placebo cream (Group 1)
Number of subjects: 40
Study 1881957 — intervention group
Group type: COMPARATOR
Intervention: Sham ultrasound using trolamine salicylate cream (Group 2)
Number of subjects: 40
Study 1881957 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound using placebo cream (Group 3)
Number of subjects: 40
Study 1881957 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound using trolamine salicylate cream (Group 4)
Number of subjects: 40
Study 6823882 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustagen with 0 mg/kg MSG
Number of subjects: 6
Study 6823882 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustagen with 100 mg/kg MSG
Number of subjects: 6
Study 6823882 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustagen with 150 mg/kg MSG
Number of subjects: 6
Study 6823882 — intervention group
Group type: COMPARATOR
Intervention: MSG in water (150 mg/kg)
Number of subjects: 6
Study 6823882 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustagen with MSG (all doses)
Number of subjects: 6
Study 30788599 — intervention group
Group type: EXPERIMENTAL
Intervention: REFS (Rehabilitation following lumbar fusion surgery)
Number of subjects: 52
Study 30788599 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 52
Study 29546309 — intervention group
Group type: EXPERIMENTAL
Intervention: Resveratrol (200 mg) and Curcumin (100 mg)
Number of subjects: 22
Study 29546309 — intervention group
Group type: COMPARATOR
Intervention: Placebo (cellulose)
Number of subjects: 22
Study 26979085 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity exercise (group A)
Number of subjects: 60
Study 26979085 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity exercise (group B)
Number of subjects: 60
Study 26979085 — intervention group
Group type: COMPARATOR
Intervention: Control group (group C)
Number of subjects: 60
Study 25548744 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan and propranolol combination therapy (26 patients)
Number of subjects: 53
Study 25548744 — intervention group
Group type: COMPARATOR
Intervention: Propranolol monotherapy (27 patients)
Number of subjects: 53
Study 21908494 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged exposure therapy plus paroxetine
Number of subjects: 37
Study 21908494 — intervention group
Group type: COMPARATOR
Intervention: Prolonged exposure therapy plus placebo
Number of subjects: 37
Study 19679245 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel
Number of subjects: 13608
Study 19679245 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 13608
Study 17456648 — intervention group
Group type: COMPARATOR
Intervention: Volume-controlled ventilation (VCV)
Number of subjects: 58
Study 17456648 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure-controlled ventilation (PCV)
Number of subjects: 58
Study 15093982 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid (5 mg/daily) for 6 weeks
Number of subjects: 50
Study 15093982 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 50
Study 11135155 — intervention group
Group type: EXPERIMENTAL
Intervention: Trendelenburg head position (‐15 degrees)
Number of subjects: 128
Study 11135155 — intervention group
Group type: COMPARATOR
Intervention: Horizontal head position (0 degrees)
Number of subjects: 128
Study 11135155 — intervention group
Group type: EXPERIMENTAL
Intervention: Trendelenburg head position (‐15 degrees) and Horizontal head position (0 degrees)
Number of subjects: 128
Study 10070517 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior chamber intraocular lenses (AC IOLs) after intracapsular cataract extraction (ICCE)
Number of subjects: 100
Study 7805078 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 0
Study 2659636 — intervention group
Group type: EXPERIMENTAL
Intervention: Occlusin
Number of subjects: 325
Study 2659636 — intervention group
Group type: COMPARATOR
Intervention: Conventional lathe cut amalgam
Number of subjects: 325
Study 1055242 — intervention group
Group type: EXPERIMENTAL
Intervention: Toothkeeper
Number of subjects: 0
Study 1055242 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional
Number of subjects: 0
Study 31178342 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary anastomosis
Number of subjects: 133
Study 31178342 — intervention group
Group type: COMPARATOR
Intervention: Hartmann's procedure
Number of subjects: 133
Study 28340861 — intervention group
Group type: EXPERIMENTAL
Intervention: Aclidinium bromide/formoterol fumarate (AB/FF) 400/12 μg
Number of subjects: 780
Study 28340861 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 780
Study 28340861 — intervention group
Group type: EXPERIMENTAL
Intervention: AB/FF combinations
Number of subjects: 780
Study 28340861 — intervention group
Group type: EXPERIMENTAL
Intervention: Monotherapies
Number of subjects: 780
Study 25996289 — intervention group
Group type: EXPERIMENTAL
Intervention: NS 440 mg/DPH 50 mg
Number of subjects: 979
Study 25996289 — intervention group
Group type: EXPERIMENTAL
Intervention: NS 440 mg/DPH 25 mg
Number of subjects: 979
Study 25996289 — intervention group
Group type: COMPARATOR
Intervention: NS 440 mg
Number of subjects: 979
Study 25996289 — intervention group
Group type: COMPARATOR
Intervention: DPH 50 mg
Number of subjects: 979
Study 24133038 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized reading intervention delivered by non-professional tutors
Number of subjects: 137
Study 24133038 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 137
Study 20978739 — intervention group
Group type: EXPERIMENTAL
Intervention: Invitation to screening for diabetes (1990-1992)
Number of subjects: 4936
Study 20978739 — intervention group
Group type: EXPERIMENTAL
Intervention: Attended screening at any time point
Number of subjects: 4936
Study 20978739 — intervention group
Group type: EXPERIMENTAL
Intervention: Did not attend screening
Number of subjects: 4936
Study 20978739 — intervention group
Group type: COMPARATOR
Intervention: Non-invited participants (2000-2003)
Number of subjects: 4936
Study 18281020 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater vitamin B6 intake
Number of subjects: 32
Study 18281020 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater vitamin B12 intake
Number of subjects: 32
Study 18281020 — intervention group
Group type: COMPARATOR
Intervention: Vitamin supplementation
Number of subjects: 32
Study 18281020 — intervention group
Group type: EXPERIMENTAL
Intervention: Folate intake
Number of subjects: 32
Study 18281020 — intervention group
Group type: COMPARATOR
Intervention: Global brain volume measures
Number of subjects: 32